The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
Open accessAbstract
INTRODUCTION: Limited clinical data are available regarding the efficacy of EGFR tyrosine kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR mutations. This pooled analysis assessed the activity of afatinib in 693 patients with tumors harboring uncommon EGFR mutations treated in randomized clinical trials, compassionate-use and expanded-access programs, phase IIIb trials, noninterventional trials, and case series or studies. METHODS: Patients had uncommon EGFR mutations, which were categorized as follows: (1) T790M; (2) exon 20 insertions; (3) "major" uncommon mutations (G719X, L861Q, and S768I, with or without any other mutation except T790M or an exon 20 insertion); (4) compound mutations; and (5) other uncommon mutations. Key end points were overall response rate (ORR), duration of response, and time to treatment failure (TTF). RESULTS: In EGFR TKI-naive patients (n = 315), afatinib demonstrated activity against major uncommon mutations (median TTF = 10.8 mo; 95% confidence interval [CI]: 8.1-16.6; ORR = 60.0%), compound mutations (median TTF = 14.7 mo; 95% CI: 6.8-18.5; ORR = 77.1%), other uncommon mutations (median TTF = 4.5 mo; 95% CI: 2.9-9.7; ORR = 65.2%), and some exon 20 insertions (median TTF = 4.2 mo; 95% CI: 2.8-5.3; ORR = 24.3%). The median duration of response for major uncommon mutations, compound mutations, other uncommon mutations, and some exon 20 insertions was 17.1, 16.6, 9.0, and 11.9 months, respectively. Activity of afatinib was also observed in EGFR TKI-pretreated patients (n = 378). A searchable database of these outcomes by individual genotype was generated. CONCLUSIONS: Afatinib has clinical activity in NSCLC against major uncommon and compound EGFR mutations. It also has broad activity against other uncommon EGFR mutations and some exon 20 insertions. The data support the use of afatinib in these settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationGefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · cited 1×
“The first-line standard of care for patients with EGFR mutation–positive NSCLC are the EGFR tyrosine kinase inhibitors (TKIs), of which five are now clinically approved: the first-generation reversible EGFR TKIs, gefitinib and erlotinib(1-6); the second-generation irreversible ErbB family blockers, afatinib and dacomi…”
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citationWu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Wu, Y.-L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Tsuji, F., Linke, R., Rosell, R., Corral, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30608-3 · Cited by 1,216
Park, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30033-x · Cited by 1,183
Self-citationYang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00026-1 · Cited by 1,002
Self-citationMiller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70087-6 · Cited by 961
Self-citationWu, Y.-L., Zhou, C., Liam, C.-K., Wu, G., Liu, X., Zhong, Z., Lu, S., Cheng, Y., Han, B., Chen, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv270 · Cited by 738
Arcila, M. E., Nafa, K., Chaft, J. E., Rekhtman, N., Lau, C., Reva, B. A., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0620 · Cited by 473
Sequist, L. V., Besse, B., Lynch, T. J., Miller, V. A., Wong, K. K., Gitlitz, B., Eaton, K., Zacharchuk, C., Freyman, A., Powell, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.9414 · Cited by 429
Kobayashi, Y., & Mitsudomi, T. (2016) · Cancer Science · doi:10.1111/cas.12996 · Cited by 413
Yang, J. C.-H., Shih, J.-Y., Su, W.-C., Hsia, T.-C., Tsai, C.-M., Ou, S.-H. I., Yu, C.-J., Chang, G.-C., Ho, C.-L., Sequist, L. V., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70086-4 · Cited by 410
Self-citationBeau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt418 · Cited by 324
Chiu, C.-H., Yang, C.-T., Shih, J.-Y., Huang, M.-S., Su, W.-C., Lai, R.-S., Wang, C.-C., Hsiao, S.-H., Lin, Y.-C., Ho, C.-L., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000504 · Cited by 241
Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
Kobayashi, S., Canepa, H. M., Bailey, A. S., Nakayama, S., Yamaguchi, N., Goldstein, M. A., Huberman, M. S., & Costa, D. B. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182781e35 · Cited by 213 · cited 1×
“Even though robust clinical trial data have demonstrated the efficacy and tolerability benefits of EGFR TKIs versus standard of care, the bulk of these trials were limited to patients whose tumors harbored the common EGFR mutations, exon 19 deletions (Del19) and L858R, which account for approximately 45% and 40% of ca…”
Naidoo, J., Sima, C. S., Rodriguez, K., Busby, N., Nafa, K., Ladanyi, M., Riely, G. J., Kris, M. G., Arcila, M. E., & Yu, H. A. (2015) · Cancer · doi:10.1002/cncr.29493 · Cited by 211
Kohsaka, S., Nagano, M., Ueno, T., Suehara, Y., Hayashi, T., Shimada, N., Takahashi, K., Suzuki, K., Takamochi, K., Takahashi, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan6566 · Cited by 210
Watanabe, S., Minegishi, Y., Yoshizawa, H., Maemondo, M., Inoue, A., Sugawara, S., Isobe, H., Harada, M., Ishii, Y., Gemma, A., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000048 · Cited by 204
Kobayashi, Y., Togashi, Y., Yatabe, Y., Mizuuchi, H., Jangchul, P., Kondo, C., Shimoji, M., Sato, K., Suda, K., Tomizawa, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1046 · Cited by 203
Uncommon EGFR mutations in advanced non-small cell lung cancer
O'Kane, G. M., Bradbury, P. A., Feld, R. D., Leighl, N. B., Liu, G., Pisters, K.-M., Kamel‐Reid, S., Tsao, M., & Shepherd, F. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.016 · Cited by 165
Blumenthal, G. M., Gong, Y., Kehl, K., Mishra-Kalyani, P., Goldberg, K. B., Khozin, S., Kluetz, P. G., Oxnard, G. R., & Pazdur, R. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz060 · Cited by 165
Kim, E. Y., Cho, E. N., Park, H. S., Hong, J. Y., Lim, S., Youn, J. P., Hwang, S. Y., & Chang, Y. S. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1139235 · Cited by 132
Self-citationYamada, T., Hirai, S., Katayama, Y., Yoshimura, A., Shiotsu, S., Watanabe, S., Kikuchi, T., Hirose, K., Kubota, Y., Chihara, Y., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2037 · Cited by 116
Floc'h, N., Martin, M. J., Riess, J. W., Orme, J. P., Staniszewska, A. D., Ménard, L., Cuomo, M. E., O'Neill, D. J., Ward, R. A., Finlay, M. R. V., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0758 · Cited by 115
Keam, B., Kim, D.-W., Park, J. H., Lee, J.-O., Kim, T. M., Lee, S.-H., Chung, D. H., & Heo, D. S. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-013-0602-1 · Cited by 113
Kim, Y., Lee, S., Ahn, J. S., Ahn, M., Park, K., & Sun, J. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.117 · Cited by 112
Self-citationApplication of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review
Sacher, A. G., Komatsubara, K. M., & Oxnard, G. R. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.022 · Cited by 104
Shen, Y.-C., Tseng, G.-C., Tu, C.-Y., Chen, W.-C., Liao, W.-C., Chen, W.-C., Li, C.-H., Chen, H.-J., & Hsia, T.-C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.007 · Cited by 99
Klughammer, B., Brugger, W., Cappuzzo, F., Ciuleanu, T., Mok, T., Reck, M., Tan, E. H., Delmar, P., Klingelschmitt, G., Yin, A.-Y., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.107 · Cited by 98
Haura, E. B., Cho, B. C., Lee, J. S., Han, J., Lee, K. H., Sanborn, R. E., Govindan, R., Cho, E. K., Kim, S., Reckamp, K. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9009 · Cited by 96
Self-citationHeymach, J. V., Negrao, M. V., Robichaux, J. P., Carter, B. W., Patel, A. P., Altan, M., Gibbons, D. L., Fossella, F. V., Simon, G. R., Lam, V. K. L., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.243 · Cited by 85
Heigener, D. F., Schumann, C., Sebastian, M., Sadjadian, P., Stehle, I., Märten, A., Lüers, A., Griesinger, F., Scheffler, M., & for the Afatinib Compassionate Use Consortium (ACUC) (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0073 · Cited by 78
Self-citationKuiper, J. L., Hashemi, S. M. S., Thunnissen, E., Snijders, P. J. F., Grünberg, K., Bloemena, E., Sie, D., Postmus, P. E., Heideman, D. A. M., & Smit, E. F. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.372 · Cited by 73
Liang, S., Hsieh, M., Lee, M., Keng, L., Ko, J., & Shih, J. (2017) · Oncotarget · doi:10.18632/oncotarget.19563 · Cited by 70
Krawczyk, P., Kowalski, D. M., Ramlau, R., Kalinka-Warzocha, E., Winiarczyk, K., Stencel, K., Powrózek, T., Reszka, K., Wojas-Krawczyk, K., Bryl, M., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.5980 · Cited by 65
Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.
Janne, P. A., Neal, J. W., Camidge, D. R., Spira, A. I., Piotrowska, Z., Horn, L., Costa, D. B., Tsao, A. S., Patel, J. D., Gadgeel, S. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9007 · Cited by 61
Passaro, A., Prelaj, A., Bonanno, L., Tiseo, M., Tuzi, A., Proto, C., Chiari, R., Rocco, D., Genova, C., Sini, C., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.11.005 · Cited by 54
Peled, N., Roisman, L. C., Miron, B., Pfeffer, R., Lanman, R. B., Ilouze, M., Dvir, A., Soussan‐Gutman, L., Barlési, F., Tarcic, G., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.02.023 · Cited by 52
Kate, S., Chougule, A., Joshi, A., Noronha, V., Patil, V., Dusane, R., Solanki, L., Tiwrekar, P., Trivedi, V., & Prabhash, K. (2019) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s181406 · Cited by 48
Liang, S., Ko, J., Yang, J. C., & Shih, J. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.019 · Cited by 48
Self-citationLin, Y.-T., Liu, Y.-N., Wu, S.-G., Yang, J. C.-H., & Shih, J.-Y. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.12.014 · Cited by 43
Self-citationPark, K., Lim, W., Okamoto, I., & Yang, J. C. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919836374 · Cited by 39
Self-citationMechanisms of acquired resistance to afatinib clarified with liquid biopsy
Nakamura, T., Nakashima, C., Komiya, K., Kitera, K., Hirai, M., Kimura, S. H., & Sueoka‐Aragane, N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209384 · Cited by 38
Schüler, M., Paz-Ares, L. G., Sequist, L. V. D., Hirsh, V., Lee, K. H., Wu, Y.-L. L. C., Lü, S., Zhou, C., Feng, J., Ellis, S. H., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.006 · Cited by 33
Self-citationLi, H., Wang, C., Wang, Z., Hu, Y., Zhang, G., Zhang, M., Zheng, X., Zhang, X., Yang, J., Ma, Z., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.02.001 · Cited by 30
Self-citationGalli, G., Corrao, G., Imbimbo, M., Proto, C., Signorelli, D., Ganzinelli, M., Zilembo, N., Vitali, M., de Braud, F., Garassino, M. C., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2017.12.002 · Cited by 29
Ma, W., Brodie, S. G., Agersborg, S. S., Funari, V. A., & Albitar, M. X. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0290-z · Cited by 28
Tanaka, I., Morise, M., Kodama, Y., Matsui, A., Ozawa, N., Ozone, S., Goto, D., Miyazawa, A., Hase, T., Hashimoto, N., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.018 · Cited by 28
Frega, S., Conte, P., Fassan, M., Polo, V., & Pasello, G. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.023 · Cited by 25
EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib
Ibrahim, U., Saqib, A., & Atallah, J. P. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.023 · Cited by 25
Ahn, M., Cho, J. H., Sun, J., Lee, S., Ahn, J. S., Park, K., Park, K. U., Kang, E. J., Choi, Y. H., Kim, K. H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9050 · Cited by 23
Self-citationMartin, J., Lehmann, A., Klauschen, F., Hummel, M., Lenze, D., Grohé, C., Tessmer, A., Gottschalk, J., Schmidt, B., Pau, H. W., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.04.012 · Cited by 23
Zhou, T., Zhou, X., Li, P., Qi, C., & Ling, Y. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.26 · Cited by 21
EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?
Raez, L. E., Pinto, J. A., Schrock, A. B., & Ali, S. M. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.005 · Cited by 20
Cappuzzo, F., Soo, R. A., Hochmair, M. J., Schüler, M., Lam, K. C., Stehle, G., Cseh, A., Lorence, R. M., Linden, S., Forman, N. D., et al. (2018) · Future Oncology · doi:10.2217/fon-2017-0666 · Cited by 16
Cai, Y., Wang, X., Guo, Y., Sun, C., Xu, Y., Qiu, S., & Ma, K. (2019) · Medicine · doi:10.1097/md.0000000000013890 · Cited by 15
Chan, R. T. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12853 · Cited by 14
Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation
Iwamoto, Y., Ichihara, E., Hara, N., Nakasuka, T., Ando, C., Umeno, T., Hirabae, A., Maeda, Y., & Kiura, K. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz086 · Cited by 14
Kimura, S., Tanaka, K., Harada, T., Liu, R., Shibahara, D., Kawano, Y., Nakanishi, Y., & Okamoto, I. (2018) · Cancer Science · doi:10.1111/cas.13787 · Cited by 13
Niogret, J., Coudert, B. P., & Boidot, R. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.02.004 · Cited by 12
Duan, H., Peng, Y., Cui, H., Qiu, Y., Li, Q., Zhang, J., Shen, W., Sun, C., & Luo, C. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s151125 · Cited by 10
Chen, L., Shih, J., Yu, C., & Yang, C. (2019) · Respirology Case Reports · doi:10.1002/rcr2.425 · Cited by 9
Brindel, A., Althakfi, W., Barritault, M., Bringuier, P., Watkin, E., Maury, J., Girard, N., & Brevet, M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.072 · Cited by 7
Efficacy and Safety Results of the Afatinib Expanded Access Program
Kim, E. S., Halmos, B., Kohut, I. F., Patel, T. N., Rostorfer, R., Spira, A. I., Cseh, A., McKay, J., Wallenstein, G., & Mileham, K. F. (2017) · Oncology and Therapy · doi:10.1007/s40487-017-0043-5 · Cited by 5
Self-citationČoupková, H., & Vyzula, R. (2018) · Klinicka onkologie · doi:10.14735/amko2018380 · Cited by 5
Ikeuchi, T., Tokuyasu, H., & Ishikawa, S. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0927-18 · Cited by 3
Cited by
Non–Small Cell Lung Cancer, Version 4.2024
Riely, G. J., Wood, D. E., Ettinger, D. S., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2204.0023 · Cited by 855
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.009 · Cited by 853
Imyanitov, E. N., Iyevleva, A. G., & Levchenko, E. V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103194 · Cited by 526
Structure-based classification predicts drug response in EGFR-mutant NSCLC
Robichaux, J. P., Le, X., Vijayan, R. S. K., Hicks, J. K., Heeke, S., Elamin, Y. Y., Lin, H. Y., Udagawa, H., Skoulidis, F., Tran, H., et al. (2021) · Nature · doi:10.1038/s41586-021-03898-1 · Cited by 490
Self-citationHanna, N. H., Schneider, B. J., Temin, S., Baker, S., Brahmer, J., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03022 · Cited by 456
Metadata
- Authors
- Yang, J. C.-H., Schuler, M., Popat, S., Miura, S., Heeke, S., Park, K., Märten, A., & Kim, E. S.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 15
- Issue
- 5
- Pages
- 803-815
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3000009976
- Cited by
- 274
- References
- 75
- FWCI
- 21.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.